Kane Biotech (KNBIF) 0.0200 $KNBIF
Kane Biotech Announces Private Placement Offering and Proposed Consolidation of Shares
Marketwire Canada - Thu Jun 02, 4:33PM CDT
WINNIPEG, MANITOBA--(Marketwired - Jun 2, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech"
today announced the intention of the Company to undertake a non-brokered private placement offering (the "Offering" of up to 50,000,000 common shares ("Common Shares" at a price of $0.03 per Common Share for gross proceeds of up to $1,500,000. The net proceeds of the Offering will be used for development and marketing of the Company's products and for general working capital.
KNE.VN: 0.030 (-0.005)
Philip Renaud Files Early Warning Report in Respect of Kane Biotech Inc.
Marketwired - Thu May 05, 5:23PM CDT
LONDON, UNITED KINGDOM--(Marketwired - May 5, 2016) - Philip Renaud (11 The Little Boltons, London, England, SW10 9LT), the Chairman and a director of Kane Biotech Inc. (the "Corporation", today announces that he and an entity over which he exercises control have acquired 28,408,146 common shares ("Common Shares" of the Corporation in connection with the Corporation's previously announced rights offering (the "Rights Offering", as described in the Corporation's Rights Offering circular dated March 30, 2016.
Kane Biotech Announces Insider Participation in Rights Offering
Marketwire Canada - Wed May 04, 5:07PM CDT
WINNIPEG, MANITOBA--(Marketwired - May 4, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech" is pleased to announce additional information regarding the participation of the insiders of the Company in the rights offering (the "Rights Offering" of the Company that closed on May 3, 2016.
KNE.VN: 0.030 (-0.005)
Kane Biotech Announces Rights Offering Closing
Marketwired - Wed May 04, 7:02AM CDT
WINNIPEG, MANITOBA--(Marketwired - May 4, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech" is pleased to announce the closing of its rights offering (the "Rights Offering" originally announced on March 29, 2016.
KNE.VN: 0.030 (-0.005)
Kane Biotech Announces bluestem(TM) Breakthrough Order with Major Retail Chain
Marketwired - Tue Apr 26, 4:50PM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Company" or "Kane Biotech" or "Kane" is pleased to announce that it has received a breakthrough order of its bluestem(TM) brand of oral care products from a major North American pet specialty store chain. The chain is one of the largest and fastest growing pet retailers in North America dedicated to providing families with food and supplies for their pets.
KNE.VN: 0.030 (-0.005)
Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest
Marketwired - Thu Apr 07, 11:30AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation" announced that on April 7, 2016, it issued 254,369 common shares of the Corporation ("Common Shares" in payment of $12,718.45 in interest owing on the Corporation's $500,000 2 year 10% convertible redeemable unsecured note (the "Note" as at March 18, 2016. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shares in lieu of cash in payment of interest on the Note at a deemed price per share equal to the market price of the Common Shares on the applicable interest payment date, subject to a minimum price of $.05 per share and the approval of the TSX Venture Exchange (the "Exchange". The approval of the Exchange for the issuance of the Common Shares was obtained by the Corporation on March 23, 2016. The Common Shares issued by the Corporation are restricted from transfer for a period of four months from the date of issuance in accordance with applicable securities laws and TSX Venture Exchange policies.
KNE.VN: 0.030 (-0.005)
Kane Biotech Announces Rights Offering
Marketwire Canada - Tue Mar 29, 3:52PM CDT
Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech" today announced that it will be offering rights ("Rights" to holders ("Shareholders" of its common shares ("Common Shares" of record as at 5:00 p.m. (Toronto time) on April 5, 2016 (the "Record Date", on the basis of one Right for each Common Share held (the "Rights Offering". Each Right will entitle the holder thereof to subscribe for one Common Share upon payment of the subscription price of $0.03 per Common Share. The Rights Offering will be conducted only in the provinces and territories of Canada (the "Eligible Jurisdictions". Accordingly, and subject to the detailed provisions of Kane Biotech's rights offering circular in respect of the Rights Offering (the "Circular", Rights will not be delivered to, nor will they be exercisable by, persons resident outside the Eligible Jurisdictions. Rather, such Rights may be sold on their behalf.
KNE.VN: 0.030 (-0.005)
Kane Biotech Announces Private Placement Offering
Marketwired - Wed Jan 27, 7:02AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Company" or "Kane Biotech" today announced the intention of the Company to undertake a non-brokered private placement offering (the "Offering" of up to 66,666,667 units ("Units" at a price of $0.06 per Unit for gross proceeds of up to $4,000,000. Each Unit shall be comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant (a "Warrant". Each whole Warrant shall entitle the holder thereof to purchase one Share at a price of $0.10 per Share for a period of 18 months from the date of issuance of the Warrant. Insiders of Kane Biotech have informed the Company they will be participating in the Offering.
KNE.VN: 0.030 (-0.005)
Kane Biotech Receives $240,000 From Warrant Exercise
Marketwired - Fri Jan 08, 7:01AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation" announced that between December 30, 2015 and January 4, 2016 it received $240,000 from the exercising of 4,000,000 warrants at $.06 per share. The warrants were issued on December 9, 2014 as part of a previous financing. The warrants were exercised by family members of an insider of the Corporation.
KNE.VN: 0.030 (-0.005)
Kane Biotech Appoints New CFO and Announces Addition of Commercialization Team Resources, Sales Representation Agreement for U.S. Market Expansion, and Grant of Options
Marketwired - Tue Jan 05, 7:02AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation", a biotechnology company developing and commercializing products that prevent and remove microbial biofilms, is pleased to appoint Audrey Goertzen CPA, CGA as Kane Biotech's new Chief Financial Officer (CFO) replacing Mark Matthewson CPA, CA, effective January 4, 2016. Ms. Goertzen has broad experience in financial management and accounting over the past 22 years in public accounting, public and government crown corporations, as well as rapidly growing entrepreneurial companies. Mr. Matthewson's services had been provided to Kane Biotech through a Management Services Agreement with MKM Management Services Ltd.
KNE.VN: 0.030 (-0.005)
Philip Renaud Files Updated Early Warning Report in Respect of Kane Biotech Inc.
Marketwired - Wed Dec 16, 5:01AM CST
Philip Renaud, the Chairman and a director of Kane Biotech Inc. (the "Corporation", today announces that he and the Corporation have entered into an agreement to: (a) extend the maturity date of the $500,000 principal amount 2-year 10% convertible redeemable unsecured note previously issued to him by the Corporation (the "Note" from December 18, 2015 to June 18, 2017; and (b) change the price at which the Note may be converted into common shares of the Corporation ("Common Shares" from $0.15 per Common Share to $0.10 per Common Share. This decrease in conversion price increases the potential number of Common Shares issuable upon the conversion of the Note from 3,333,333 to 5,000,000; such increase represents approximately 1.4% of the issued and outstanding Common Shares. All other terms of the Note remain the same. In addition, Mr. Renaud and the Corporation have also entered into an agreement to extend the time during which 4,000,000 warrants to purchase Common Shares (the "Warrants" previously issued to Mr. Renaud may be exercised from December 18, 2015 to June 18, 2017. All other terms of the Warrants remain the same, including the exercise price of $0.095 per Common Share. For the purposes hereof, the foregoing amendments shall be referred to as the "Amendments".
Kane Biotech Announces Private Placement Offering and Proposed Consolidation of Shares
Marketwire Canada - Thu Jun 02, 4:33PM CDT
WINNIPEG, MANITOBA--(Marketwired - Jun 2, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech"
today announced the intention of the Company to undertake a non-brokered private placement offering (the "Offering" of up to 50,000,000 common shares ("Common Shares" at a price of $0.03 per Common Share for gross proceeds of up to $1,500,000. The net proceeds of the Offering will be used for development and marketing of the Company's products and for general working capital. KNE.VN: 0.030 (-0.005)
Philip Renaud Files Early Warning Report in Respect of Kane Biotech Inc.
Marketwired - Thu May 05, 5:23PM CDT
LONDON, UNITED KINGDOM--(Marketwired - May 5, 2016) - Philip Renaud (11 The Little Boltons, London, England, SW10 9LT), the Chairman and a director of Kane Biotech Inc. (the "Corporation"
, today announces that he and an entity over which he exercises control have acquired 28,408,146 common shares ("Common Shares" of the Corporation in connection with the Corporation's previously announced rights offering (the "Rights Offering", as described in the Corporation's Rights Offering circular dated March 30, 2016. Kane Biotech Announces Insider Participation in Rights Offering
Marketwire Canada - Wed May 04, 5:07PM CDT
WINNIPEG, MANITOBA--(Marketwired - May 4, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech"
is pleased to announce additional information regarding the participation of the insiders of the Company in the rights offering (the "Rights Offering" of the Company that closed on May 3, 2016. KNE.VN: 0.030 (-0.005)
Kane Biotech Announces Rights Offering Closing
Marketwired - Wed May 04, 7:02AM CDT
WINNIPEG, MANITOBA--(Marketwired - May 4, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech"
is pleased to announce the closing of its rights offering (the "Rights Offering" originally announced on March 29, 2016. KNE.VN: 0.030 (-0.005)
Kane Biotech Announces bluestem(TM) Breakthrough Order with Major Retail Chain
Marketwired - Tue Apr 26, 4:50PM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Company" or "Kane Biotech" or "Kane"
is pleased to announce that it has received a breakthrough order of its bluestem(TM) brand of oral care products from a major North American pet specialty store chain. The chain is one of the largest and fastest growing pet retailers in North America dedicated to providing families with food and supplies for their pets. KNE.VN: 0.030 (-0.005)
Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest
Marketwired - Thu Apr 07, 11:30AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation"
announced that on April 7, 2016, it issued 254,369 common shares of the Corporation ("Common Shares" in payment of $12,718.45 in interest owing on the Corporation's $500,000 2 year 10% convertible redeemable unsecured note (the "Note" as at March 18, 2016. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shares in lieu of cash in payment of interest on the Note at a deemed price per share equal to the market price of the Common Shares on the applicable interest payment date, subject to a minimum price of $.05 per share and the approval of the TSX Venture Exchange (the "Exchange". The approval of the Exchange for the issuance of the Common Shares was obtained by the Corporation on March 23, 2016. The Common Shares issued by the Corporation are restricted from transfer for a period of four months from the date of issuance in accordance with applicable securities laws and TSX Venture Exchange policies. KNE.VN: 0.030 (-0.005)
Kane Biotech Announces Rights Offering
Marketwire Canada - Tue Mar 29, 3:52PM CDT
Kane Biotech Inc. (TSX VENTURE:KNE) (the "Company" or "Kane Biotech"
today announced that it will be offering rights ("Rights" to holders ("Shareholders" of its common shares ("Common Shares" of record as at 5:00 p.m. (Toronto time) on April 5, 2016 (the "Record Date", on the basis of one Right for each Common Share held (the "Rights Offering". Each Right will entitle the holder thereof to subscribe for one Common Share upon payment of the subscription price of $0.03 per Common Share. The Rights Offering will be conducted only in the provinces and territories of Canada (the "Eligible Jurisdictions". Accordingly, and subject to the detailed provisions of Kane Biotech's rights offering circular in respect of the Rights Offering (the "Circular", Rights will not be delivered to, nor will they be exercisable by, persons resident outside the Eligible Jurisdictions. Rather, such Rights may be sold on their behalf. KNE.VN: 0.030 (-0.005)
Kane Biotech Announces Private Placement Offering
Marketwired - Wed Jan 27, 7:02AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Company" or "Kane Biotech"
today announced the intention of the Company to undertake a non-brokered private placement offering (the "Offering" of up to 66,666,667 units ("Units" at a price of $0.06 per Unit for gross proceeds of up to $4,000,000. Each Unit shall be comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant (a "Warrant". Each whole Warrant shall entitle the holder thereof to purchase one Share at a price of $0.10 per Share for a period of 18 months from the date of issuance of the Warrant. Insiders of Kane Biotech have informed the Company they will be participating in the Offering. KNE.VN: 0.030 (-0.005)
Kane Biotech Receives $240,000 From Warrant Exercise
Marketwired - Fri Jan 08, 7:01AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation"
announced that between December 30, 2015 and January 4, 2016 it received $240,000 from the exercising of 4,000,000 warrants at $.06 per share. The warrants were issued on December 9, 2014 as part of a previous financing. The warrants were exercised by family members of an insider of the Corporation. KNE.VN: 0.030 (-0.005)
Kane Biotech Appoints New CFO and Announces Addition of Commercialization Team Resources, Sales Representation Agreement for U.S. Market Expansion, and Grant of Options
Marketwired - Tue Jan 05, 7:02AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation"
, a biotechnology company developing and commercializing products that prevent and remove microbial biofilms, is pleased to appoint Audrey Goertzen CPA, CGA as Kane Biotech's new Chief Financial Officer (CFO) replacing Mark Matthewson CPA, CA, effective January 4, 2016. Ms. Goertzen has broad experience in financial management and accounting over the past 22 years in public accounting, public and government crown corporations, as well as rapidly growing entrepreneurial companies. Mr. Matthewson's services had been provided to Kane Biotech through a Management Services Agreement with MKM Management Services Ltd. KNE.VN: 0.030 (-0.005)
Philip Renaud Files Updated Early Warning Report in Respect of Kane Biotech Inc.
Marketwired - Wed Dec 16, 5:01AM CST
Philip Renaud, the Chairman and a director of Kane Biotech Inc. (the "Corporation"
, today announces that he and the Corporation have entered into an agreement to: (a) extend the maturity date of the $500,000 principal amount 2-year 10% convertible redeemable unsecured note previously issued to him by the Corporation (the "Note" from December 18, 2015 to June 18, 2017; and (b) change the price at which the Note may be converted into common shares of the Corporation ("Common Shares" from $0.15 per Common Share to $0.10 per Common Share. This decrease in conversion price increases the potential number of Common Shares issuable upon the conversion of the Note from 3,333,333 to 5,000,000; such increase represents approximately 1.4% of the issued and outstanding Common Shares. All other terms of the Note remain the same. In addition, Mr. Renaud and the Corporation have also entered into an agreement to extend the time during which 4,000,000 warrants to purchase Common Shares (the "Warrants" previously issued to Mr. Renaud may be exercised from December 18, 2015 to June 18, 2017. All other terms of the Warrants remain the same, including the exercise price of $0.095 per Common Share. For the purposes hereof, the foregoing amendments shall be referred to as the "Amendments". 
